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The utilisation of antitumour T cells induced by cancer vaccination with HER-2 peptides or antibodies (Herceptin) against HER-2, as
immunotherapy for oesophageal cancer, is a novel and attractive approach. It is important to clarify the frequencies of HER-2
expression and gene amplification in patients with oesophageal squamous cell carcinoma (SCC) and to evaluate the relationship
between HER-2 status and HLA haplotype, since the candidates for HER-2 peptide-based vaccination are restricted to a certain HLA
haplotype. We determined the frequency of HER-2 expression using the HercepTestt for immunohistochemistry and HER-2 gene
amplification by fluorescence in situ hybridisation (FISH) assay in oesophageal SCC (n¼66). HER-2-positive tumours (1þ/2þ/3þ)
analysed by a HercepTest were observed in 30.3% of all the patients and HER-2 gene amplification evaluated by FISH was observed
in 11.0% of all the patients, in which all HercepTest (3þ) tumours were found to have gene amplification and three of six moderately
positive (2þ) tumours showed gene amplification. Furthermore, HER-2-positive cells were present more diffusely and were larger
within each tumour in the patients who were HercepTest 3þ than those who were HercepTest 1þ. Moreover, the survival rate in
HER-2-positive group was significantly worse than that in HER-2-negative group. Also, the survival rate in the patients with HER-2
gene amplification was significantly worse than that without HER-2 gene amplification. In addition, oesophageal SCC patients with
both HLA-A24-positive and HER-2-positive tumours (1þ/2þ/3þ) accounted for 26% of these cases, and both HLA-A2- and
HER-2-positive tumours accounted for 18% of them.
British Journal of Cancer (2005) 92, 1253–1260. doi:10.1038/sj.bjc.6602499 www.bjcancer.com
Published online 22 March 2005
& 2005 Cancer Research UK
Keywords: HER-2/neu; FISH; immunohistochemistry; HLA; immunotherapy
                                                   
While most patients with oesophageal cancer in Western countries
have adenocarcinoma, most of those in Japan have squamous cell
carcinoma (SCC). Despite various treatments such as surgical
resection with extensive lymphadenectomy (Maillet et al, 1982;
Altorki and Skinner, 1990; Kato et al, 1991; Akiyama et al, 1994)
and the surgery combined with chemotherapy (Hayashi et al,
2001) and/or radiotherapy (Le Prise et al, 1995; Adham et al, 2000;
Ishikura et al, 2003), the prognosis for advanced patients with
oesophageal SCC remains poor. The utilisation of antitumour T
cells or antibodies against tumour antigens, as immunoadjuvant
therapy for oesophageal SCC, is therefore an attractive approach.
The HER-2/neu (designated as HER-2) proto-oncogene located
on chromosome 17(17q12–q21.32) (Popescu et al, 1989) encodes a
185-kDa transmembrane glycoprotein with tyrosine-specific ki-
nase activity (Coussens et al, 1985). The HER-2 proto-oncogene is
amplified and overexpressed in approximately 30% of human
ovarian and breast tumours (Slamon et al, 1989), and in 8.2% of
gastric cancers (Takehana et al, 2002). The humanised monoclonal
antibody (mAb) Herceptin, which specifically targets HER-2,
exhibits potent growth inhibitory activity against HER-2-over
expressing tumours (Sliwkowski et al, 1999). Herceptin has
boosted the interest of clinicians in immunotherapy based on this
molecule as it represents the first mAb approved for therapeutic
use with proved survival benefit in patients with HER-2-positive
breast cancer with metastasis (Baselga et al, 1996; Slamon et al,
2001). Moreover, abundant examples from experimental models
and clinical trials suggest that HER-2 can be immunogenic and
generate antibodies, CTL- and helper T-cell-specific responses in
individuals with HER-2-overexpressing tumours (Fisk et al, 1995;
Kono et al, 1998). Based on the above reports, anti-HER-2 immune
targeting could be utilised as an attractive approach to treat
oesophageal cancer. Thus, it is important to clarify the frequency
of HER-2 expression and gene amplification relating to the HLA
haplotype in order to determine possible candidates for HER-2-
based immunotherapy, since the candidates for HER-2 peptide-
based vaccination are restricted to a certain HLA haplotype.
With respect to oesophageal SCC, the frequencies of HER-2
overexpression analysed by immunohistochemistry (IHC) ranged
from 0 to 55.9% (Mori et al, 1987; Chang et al, 1992; Suo et al,
1992; Shiga et al, 1993; Suwanagool et al, 1993; Suo et al, 1995;
Hardwick et al, 1997; Lam et al, 1998; Akamatsu et al, 2003).
Furthermore, reports describing HER-2 gene amplification ranged
from 0 to 25%, and these studies were performed by Northern blot,
slot blot or RT–PCR analysis (Shiga et al, 1993; Ikeda et al, 1996;
Tanaka et al, 1997; Friess et al, 1999). The discrepancy in the HER-
2 frequencies among the reports may be related to the
methodology, including the different mAbs used in IHC or
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sinaccurate analysis for gene amplification. There has been no
previous report describing HER-2 gene amplification in oesopha-
geal SCC analysed by fluorescence in situ hybridisation (FISH)
analysis.
In the present study, we determined the exact frequency of HER-
2 abnormalities using the HercepTestt for IHC and the PathVy-
sion test for FISH in oesophageal SCC, and analysed patient’s data
for the survival rate. Both the HercepTest and the PathVysion FISH
assay are approved by the US Food and Drug Administration
(FDA) for determining the eligibility for Herceptin treatment in
breast carcinoma. Furthermore, we have evaluated a possible
candidate for anti-HER-2 immune targeting therapy for oesopha-
geal SCC.
MATERIALS AND METHODS
Patients and samples
In all, 66 consecutive patients with primary oesophageal SCC who
were histologically diagnosed and treated in the First Department
of Surgery, University of Yamanashi Hospital, between 1998 and
1999, were enrolled in the present study and all the patients were
followed up for 5 years. None of the patients had received any
treatment before surgery (preoperative radiotherapy or che-
motherapy) and all patients had undergone oesophagectomy with
two-field (n¼39) or three-field (n¼27) lymph node dissection.
The patients were classified using the tumour node metastasis
(TNM) classification. The characteristics of the patients are shown
in Table 1. The study was approved by the ethical committee of
University of Yamanashi and written informed consent was
obtained from all individuals.
Formalin-fixed, paraffin-embedded tissue blocks were used for
IHC and FISH analysis.
HLA class I typing
Heparinised peripheral blood was obtained from patients prior to
the operation. Peripheral blood lymphocytes (PBLs) were purified
by centrifugation on a Ficoll gradient (Pharmacia, Uppsala,
Sweden). For class I typing, PBLs were subjected to a comple-
ment-dependent microcytotoxicity assay using antisera to HLA-A
loci. Peripheral blood lymphocytes were typed for A loci 1, 2, 3, 9,
10, 11, 19, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 36, 43, 66, 68, 69
and 74.
IHC analysis
Immunohistochemical staining was performed using the Hercep-
Testt (DaKoCytomation, Denmark) according to the manufac-
turer’s recommendations. Archival, formalin-fixed, paraffin-
embedded material was used to obtain 4-mm-thick sections from
the main tumour and the regional lymph nodes. Briefly,
deparaffinised and rehydrated tissue sections were incubated with
the Epitope Retrieval Solution in a heat water bath for 40min at
95–991C. Then, the sections were cooled at room temperature for
20min and washed with TRIS buffer for 5min. Next, endogenous
peroxidase was blocked with 3% hydrogen peroxide for 5min. The
primary antibody was a rabbit polyclonal antibody to human HER-
2, which recognises an intracytoplasmic part of HER-2, and the
primary negative control antibody was an immunoglobulin
fraction of normal rabbit serum at an equivalent protein
concentration as the antibody to HER-2. The sections were washed
with a TRIS buffer for 5min and incubated with the primary
antibody or the primary negative control antibody at room
temperature for 30min. After rewashing with a TRIS buffer for
5min 2 times, the primary antibody was detected using the
Visualisation Reagents, which were a dextran polymer conjugated
with horseradish peroxidase and affinity-isolated goat anti-rabbit
immunoglobulins, for 30min of incubation at room temperature.
Subsequently, following rewashing with TRIS buffer for 5min 2
times, diaminobenzidine was added as a visualisation reagent for
10min and the section was counterstained with haematoxylin.
Control slides provided with the HercepTestt kit, which contained
three human breast cancer cell lines with staining intensity scores
of 0, 1þ and 3þ, were used in the present study. IHC analysis was
performed by two observers (KM and KK) according to the
staining intensity scores provided by the HercepTestt kit. Each
section was classified into four categories (0, 1þ,2 þ,3 þ), in
which tumour cells with complete absence of staining were scored
as 0, those with incomplete membranous staining were classified as
1þ, those with moderate, complete membranous staining were
classified as 2þ and those with strong, complete membranous
staining were classified as 3þ (Figure 1).
Furthermore, we evaluated the immunostaining pattern into two
patterns, spot type or diffuse type (Figure 2), in which the diffuse
type indicated tumour cells with membranous staining spread
throughout the tumour tissue continuously. On the other hand, the
spot type indicated tumour cells with membranous staining on one
part or several parts separately in the section.
FISH analysis
FISH analysis was performed using the PathVysion
s HER-2 DNA
Probe Kit (VYSIS, Downers Grove, IL, USA). The HER-2/neu-
SpectrumOrange probe is specific for the HER-2 gene locus
(17q11.2–q12). The CEP 17 (chromosome enumeration probe)/
SpectrumGreen probe is specific for the alpha-satellite DNA
sequence (centromere region of chromosome 17). To determine
the copy number for chromosome 17, we used CEP 17 as the
control. FISH procedures were conducted according to the
manufacturer’s guidelines, except the removal of the protein from
Table 1 Clinical features of the patients (n¼66)
Age (years old)
Mean 65.3
Range 45–81
Gender
Male 62
Female 4
Primary tumour
a
pTis 2
pT1a 8
pT1b 18
pT2 5
pT3 32
LNM
Negative 29
Positive 37
SCC differentiation
Well differentiated 15
Moderate differentiated 35
Poorly differentiated 14
Stage
a
09
I5
II 25
III 19
Iva 6
Ivb 1
LNM¼lymph node metastasis; SCC¼squamous cell carcinoma.
aThe grade of
tumour and stages were defined according to the UICC (TMN) classification.
HER-2 in oesophageal squamous cell carcinoma
K Mimura et al
1254
British Journal of Cancer (2005) 92(7), 1253–1260 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe section where we used our own protocol as described
previously (Takehana et al, 2002). Briefly, sections were depar-
affinised, dehydrated and incubated in 20% sodium bisulphate/
2 standard saline citrate at 431C for 20min. Sections were
washed with SCC and treated with proteinase K (Boehringer-
Mannheim, Mannheim, Germany) at 371C for 25min. Subse-
quently, denaturation, hybridisation and posthybridisation wash-
ing were performed according to the manufacturer’s guidelines,
and after hybridisation and posthybridisation washing, the
sections were counterstained with DAPI (40,6-diamidine-20-phe-
nylindole dihydrochloride). FISH analysis was performed using a
fluorescence microscope (Olympus, Tokyo, Japan) equipped with
Triple Bandpass Filter sets (Vysis). Signals were counted for at
least 40 cancer nuclei per tumour. In accordance with earlier
studies with FISH, a cell was considered to show amplification
when a definite cluster or more than 10 orange signals of HER-2
was observed (Takehana et al, 2002). A positive control, which is
breast tumour with previously identified HER-2 amplification and
overexpression, was used as a positive control for HER-2 FISH.
Statistical analysis
The w
2 test was applied to examine the differences in frequencies of
the HLA-A haplotype and HER-2 expression in oesophageal SCC,
the differences in HercepTest score and the rate of HER-2-positive
cells in each tumour, and the differences in the lymph node
metastasis of HER-2-positive patients and HER-2-negative pa-
tients. Actuarial overall survival rates were analysed by the
Kaplan–Meier method and survival was measured in months
Figure 1 Representative immunostaining of HER-2-positive cells. (A)
1þ staining cases, (B)2 þ staining cases and (C)3 þ staining cases.
Original magnification  200.
Figure 2 Heterogeneity in the pattern of HER-2 immunostaining. The
staining pattern was categorised as spot type and diffuse type. (A) Spot
type and (B) diffuse type. Original magnification  100.
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sfrom operation to death or last review. The log-rank test was
applied to compare with the two groups. Univariate and multi-
variate survival analysis were calculated according to Cox’s
proportional-hazards model. All statistical analyses were per-
formed using Statview 5.0 for Windows software and statistically
significant difference was considered as P-values o0.05.
RESULTS
Frequencies of HER-2 expression and gene amplification
We studied 66 oesophageal SCC tumours and their regional lymph
nodes. In IHC, each section was classified into four categories
(negative, 1þ,2þ,3þ) according to the staining intensity scores
provided by the HercepTest kit. Positive immunostaining (1þ/
2þ/3þ) of HER-2 expression was found in 20 (30.3%) of the 66
patients with oesophageal SCC (Table 2). The clinicopathological
data and their FISH analysis are summarised in Table 3. Three
patients (4.5%) showed strong positive staining (3þ) and 6 (9.1%)
showed moderate positive staining (2þ).
With respect to FISH, a cell was considered to show amplifica-
tion when a definite cluster or more than 10 orange signals of
HER-2 was observed in accordance with earlier studies with FISH
(Takehana et al, 2002). In FISH analysis for IHC-positive
oesophageal SCC (n¼20), HER-2 gene amplification (cluster,
Figure 3) was found in seven tumours (Table 3). In the three
tumours, cancer nuclei showed more than three HER-2 signals
accompanied with the same number of centromere 17 signals.
They were judged as polysomy 17 (Table 3).
With respect to the comparison of FISH and IHC analysis, all the
strong positive (3þ) tumours were found to have gene amplifica-
tion, as shown in Table 3. Among six moderate positive (2þ)
tumours, three showed gene amplification (cluster) and one
showed polysomy. In 11 weak positive (1þ) tumours, one showed
gene amplification (cluster) and two showed polysomy.
Taken together, positive immunostaining (1þ/2þ/3þ) for
HER-2 expression was found in 30.3%. Moreover, moderate and
strong positive patients (2þ/3þ) had a high frequency of gene
amplification, while weak positive (1þ) patients showed a low
frequency of gene amplification.
Immunostaining pattern and rate of HER-2-positive cells
within each tumour
When the clinical application of anti-HER-2 immune targeting is
considered, it is important to clarify the heterogeneity in the
pattern of HER-2-positive tumour cells within each tumour.
According to the DAKO HercepTest kit, the grading of the
HercepTest depends on the intensity of membranous staining,
indicating that the grading does not reflect how many cells are
HER-2 positive. Thus, in the present study, we evaluated the
immunostaining pattern and rate of HER-2-positive cells within
the tumour.
We recognised that there was heterogeneity in the pattern of
HER-2 immunostaining and categorised the staining pattern into a
spot type and diffuse type (Figure 2). Also, HER-2-positive cells
were semiquantified by counting the average number in each
tumour. As a result, all three strong positive (3þ) cases showed
the diffuse-type pattern (Table 3) and had HER-2-positive cells in
more than 30% of tumours (Table 4), while most of the weak
positive (1þ) patients showed that HER-2-positive cells were less
than 30% (Table 4) (P¼0.057, w
2 analysis). Thus, HER-2-positive
Table 2 Frequencies of HER-2-positive patients detected by IHC in
oesophageal SCC
Patients (total¼66)
IHC scores
3+ 3 (4.5%)
2+ 6 (9.1%)
1+ 1 1 (16.7%)
IHC¼immunohistochemistry; SCC¼squamous cell carcinoma.
Table 3 Patients with HER-2-positive oesophageal SCC detected by IHC and their FISH analyses
IHC
Case number Age (years) Sex Stage
a Histological
b classification Score
c Pattern Score
c of LN FISH
1 73 M III Mod 3+ Diffuse 3+ Cluster
2 54 M III Por 3+ Diffuse 3+ Cluster
3 62 M IVa Mod 3+ Diffuse 3+ Cluster
4 62 M IVa Mod 2+ Spot 0 Cluster
5 59 M III Well 2+ Diffuse 0 Cluster
6 57 M III Mod 2+ Spot 2+ Polysomy
7 55 M II Por 2+ Diffuse 2+ No amplification
8 69 M II Well 2+ Spot No No amplification
9 76 M I Well 2+ Spot No Cluster
10 56 M II Mod 1+ Spot 0 Polysomy
11 74 M III Well 1+ Diffuse 0 Polysomy
12 60 M III Mod 1+ Spot 0 No amplification
13 60 M III Por 1+ Diffuse 0 No amplification
14 64 M III Mod 1+ Diffuse 0 No amplification
15 67 M III Mod 1+ Diffuse 0 No amplification
16 71 M III Mod 1+ Spot 0 No amplification
17 47 F II Por 1+ Diffuse 1+ No amplification
18 74 M 0 Por 1+ Spot No Cluster
19 70 M II Mod 1+ Diffuse No No amplification
20 80 M II Por 1+ Spot No No amplification
SCC¼squamous cell carcinoma; IHC¼immunohistochemistry; FISH¼fluorescence in situ hybridisation; LN¼lymph node; No¼no lymph node metastasis.
aStages were
defined according to the TNM classification.
bWell¼well-differentiated SCC; mod¼moderately differentiated SCC; por¼poorly differentiated SCC.
cIHC score was defined by
the staining intensity of tumour cells (0, 1+, 2+, 3+).
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scells were present more diffusely within each tumour in the
HercepTest 3þ patients than those who were HercepTest 1þ.
Correlation of HER-2 expression in primary tumours and
metastatic lymph nodes
Of all 66 cohorts, 37 (56.1%) had metastatic lymph nodes
diagnosed by histopathological determination. While 15 (75.0%)
in the 20 HER-2-positive patients had metastatic lymph nodes, 22
(47.8%) in the 46 HER-2-negative patients had metastatic lymph
nodes (Table 3), indicating that there was a high frequency of
lymph node metastasis in the HER-2-positive patients in
comparison to HER-2-negative patients (Po0.05, w
2 analysis).
All the strongly positive (3þ) patients in the primary tumours
were found to have HER-2-positive tumours (3þ) in the
metastatic lymph nodes, while there was only one patient with a
HER-2-positive tumour in the metastatic lymph node in the weak
positive (1þ) patients with lymph node metastasis (n¼8).
Frequency of the HLA haplotype relating to HER-2 status
When anti-HER-2 immunotherapy such as cancer vaccination is
considered for HER-2-positive patients, the candidates are
restricted to a certain HLA haplotype (Kono et al, 2002a). It is
important to clarify the HER-2 status relating to the HLA
haplotype in patients with oesophageal SCC. In the patients tested
for HLA haplotypes (n¼50), the distribution of the HLA-A
haplotype in patients with oesophageal SCC is shown in Table 5.
The most frequent HLA-A haplotypes in oesophageal SCC are
HLA-A24 (64%), HLA-A2 (52%) and HLA-A11 (28%). Also,
oesophageal cancer patients with both HLA-A24-positive and
HER-2-positive tumours accounted for 26% of these cases, and
both HLA-A2-positive and HER-2-positive tumours accounted
for 18% of them. There was no significant relation between
the frequency of the HLA-A haplotype and the HER-2 status
(Table 5).
Analysis of the survival of patients with oesophageal SCC
The survival rate in HER-2-positive (1þ/2þ/3þ) group was
significantly worse than that in HER-2-negative group (Figure 4A).
Moreover, there was a significant difference in the survival rate
between HER-2 (2þ/3þ) and HER-2-negative group (Figure 4B).
The survival rate in the patients with HER-2 gene amplification
was significantly worse than that without HER-2 gene amplifica-
tion (Figure 5).
In univariate analysis, the factors such as HER-2 gene
amplification, pT2 and pT3, lymph node metastasis, stages 3–4
were significant prognostic factors for survival (Table 6),
although only pT2 factor reached to the significant level as
independent risk factors for survival in multivariate analysis
(Table 6).
Figure 3 Representative FISH analysis of HER-2 gene amplification
(cluster formation). The serial sections in the representative case were
analysed by IHC (A)( 3þ staining cases,  400) and FISH analysis ( 400
in (B)).
Table 4 Correlation between IHC scores and the rate of HER-2-positive
tumour cells in each tumour
Rate of HER-2/neu-positive cells in each section
B30 (%) 31–60 (%) 61B (%)
IHC scores
3+ (n¼3) 0 2 1
2+ (n¼6) 5 0 1
1+ (n¼11) 8 1 2
P¼0.057 by w
2 test
IHC¼immunohistochemistry.
Table 5 Frequencies of the HLA-A haplotype related to HER-2
expression in oesophageal SCC (n¼50)
HER-2 status detected by IHC
Positive (n¼18) Negative (n¼32)
HLA-A2
Positive (n¼26) 9 (18%)
a 17 (34%)
Negative (n¼24) 9 (18%) 15 (30%) NS
b
HLA-A11
Positive (n¼14) 7 (14%) 7 (14%)
Negative (n¼36) 11 (22%) 25 (50%) NS
HLA-A24
Positive (n¼32) 13 (26%) 19 (38%)
Negative (n¼18) 5 (10%) 13 (26%) NS
SCC¼squamous cell carcinoma; HLA¼human leucocyte antigen.
aPercentage
indicates the number of patients out of all patients (n¼50).
bNot significant by w
2
test.
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sDISCUSSION
The present study contains several important findings relevant to
HER-2 status in oesophageal SCC. First, HER-2-positive tumours
(1þ/2þ/3þ) analysed by the HercepTest were observed in 30.3%
of all patients and HER-2 gene amplification evaluated by FISH
was observed in 11.0% of all patients, of which all IHC (3þ)
tumours were found to have gene amplification and three out of
six tumours with moderate positive (2þ) tumours showed gene
amplification. Second, HER-2-positive cells existed more diffusely
and were larger within each tumour in HercepTest 3þ patients
than those who were HercepTest 1þ. Thirdly, oesophageal SCC
patients with both HLA-A24-and HER-2-positive tumours (1þ/
2þ/3þ) accounted for 26% of these cases, and both HLA-A2- and
HER-2-positive tumours accounted for 18% of them.
The frequencies of HER-2 overexpression in oesophageal SCC
analysed by IHC ranged from 0 to 55.9% (Mori et al, 1987; Chang
0 10 20 30 40 50 60
Time after operation (months)
01 0 2 0 3 0 4 0 5 0 6 0
Time after operation (months)
HER-2 negative  (n=46)
HER-2 positive (n=20)
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
Log-rank test, P = 0.049 
HER-2 negative  (n=46)
Log-rank test, P = 0.05
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
HER-2 (2+, 3+) (n=9)
A
B
Figure 4 (A) Survival curves of HER-2-negative and HER-2-positive
(1þ/2þ/3þ) groups. (B) Survival curves of HER-2-negative and HER-2
(2þ/3þ) groups.
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Figure 5 Survival curves of HER-2 gene amplification-negative and HER-
2 gene amplification-positive groups.
Table 6 Significance of prognostic factors in univariate and multivariate survival analysis for patients with oesophageal SCC
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
FISH
Negative 1.0 — — 1.0 — —
Positive 4.05 1.31–12.53 0.015 2.94 0.78–11.09 0.111
HER-2 expression
Negative 1.00 — — 1.0 — —
Positive 2.06 0.93–4.57 0.074 0.92 0.35–2.41 0.861
Primary tumour
a
pTis-pT1b 1.0 — — 1.0 — —
pT2 5.85 1.56–21.91 0.009 5.00 1.06–23.52 0.042
pT3 5.28 1.91–14.55 0.001 3.01 0.76–11.95 0.117
LNM
Negative 1.0 — — 1.0 — —
Positive 3.13 1.32–7.39 0.009 1.56 0.25–9.68 0.636
Stage
a
0–II 1.0 — — 1.0 — —
III–IV 5.21 2.33–11.64 o0.0001 2.09 0.30–14.53 0.458
SCC¼squamous cell carcinoma; CI¼confidence interval; FISH¼fluorescence in situ hybridisation; LNM¼lymph node metastasis.
aThe grade of tumour and stages were
defined according to the UICC (TMN) classification.
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set al, 1992; Suo et al, 1992, 1995; Shiga et al, 1993; Suwanagool
et al, 1993; Lam et al, 1998; Hardwick et al, 1997; Akamatsu et al,
2003). Furthermore, reports describing HER-2 gene amplification
ranged from 0 to 25%, in which these studies were performed by
Northern blot, slot blot or RT–PCR analysis (Shiga et al, 1993;
Ikeda et al, 1996; Tanaka et al, 1997; Friess et al, 1999). This is the
first report describing the HER-2 status in oesophageal SCC
analysed by two FDA-approved tests, the HercepTest and FISH
(PathVysion test). Moreover, there was no previous report
describing HER-2 status evaluated by the HercepTest and FISH
in relation to the survival rate in oesophageal SCC. As a result,
HER-2-positive tumours analysed by the HercepTest were
observed in 30.3% of all the patients and HER-2 gene amplification
evaluated by FISH was observed in 11.0% of all the patients.
There is increasing evidence that there is a discrepancy in the
detection of HER-2 status between the two FDA-approved test, the
HercepTest and FISH (PathVysion test), in which the concordance
rates ranged from 80 to 90% (Jacobs et al, 1999; Varshney et al,
2004). There have been several reports that cases with HER-2
overexpression without gene amplification mostly occurred in
moderate positive cases (2þ) (Perez et al, 2002; Varshney et al,
2004), in line with this study. Various explanations of this
discrepancy have been proposed: transcriptional or post-transla-
tional activation (Slamon et al, 1989), artifactual high sensitivity of
IHC (Varshney et al, 2004), the presence of chromosome 17
polysomy (Wang et al, 2002) or the low detection rate of FISH
analysis (Jacobs et al, 1999). We found one case of polysomy in
2þ patients and two cases of polysomy in 1þ patients, suggesting
that the presence of chromosome 17 polysomy might be one
explanation for the discrepancy between the HercepTest and FISH
in oesophageal SCC.
Interestingly, there was one case with HER-2 gene amplification
in a HercepTest 1(þ) tumour, indicating that the screening of
HER-2 status by the HercepTest may underestimate HER-2 gene
amplification. Since both the HercepTest and FISH assay have
limitations in detecting HER-2 status, both methods should be
applied when anti-HER-2 immune targeting, such as Herceptin or
cancer vaccination, are considered in oesophageal SCC.
In this study, all the HercepTest 3þ patients had HER-2 gene
amplification, and HER-2-positive cells in these cases were present
diffusely and were larger within the tumours. Furthermore, the
HER-2 expression in HercepTest 3þ patients was also preserved
in the metastatic lymph nodes. The action of anti-HER-2-specific
CTL correlated to the degree of HER-2 expression on the target
tumour cells (Fisk et al, 1995; Kono et al, 1998). Also, the activity
of ADCC induced by Herceptin correlated to the degree of HER-2
expression on the target tumour cells (Kono et al, 2002b). These
results indicate that HercepTest 3þ patients in oesophageal SCC
will be the best candidates for anti-HER-2 immune targeting. It has
already been shown in breast cancer trials that there is a greater
benefit from Herceptin therapy for 3þ patients compared to those
who were 2þ (Cobleigh et al, 1999; Slamon et al, 2001).
The survival rate in patients with HER-2 expression or HER-2
gene amplification was significantly worse than that without HER-
2 expression or HER-2 gene amplification. These results indicated
that HER-2 status may be one of the prognostic factors to predict
the clinical course of patients with oesophageal SCC, although the
HER-2 status did not reach to the significant level as independent
risk factors for survival in multivariate analysis in the present
study. Since the sample size of the present study is limited, further
studies with larger cohorts will be needed to draw valid conclusion.
When considering the cancer vaccination with HER-2-derived
peptide epitopes, there is an HLA restriction. It has been shown
that HLA-A2- or HLA-A24-restricted peptide epitopes were
identified for immunodominant CTL epitopes derived from
HER-2 (Fisk et al, 1995; Kono et al, 1998, 2002b). In the present
study, oesophageal SCC patients with both HLA-A24- and HER-2-
positive tumours (1þ/2þ/3þ) accounted for 26% of these cases,
and both HLA-A2- and HER-2-positive tumours accounted for
18% of them. These populations are considered for cancer
vaccination with the HER-2 peptide in oesophageal SCC. In fact,
we and others reported that clinical vaccination trials in gastric or
breast cancer patients using DCs pulsed with HER-2 peptides
confirmed the fact that vaccination with HER-2 peptides is
immunogenic, and that HER-2 could be a good target for
immunotherapy (Disis et al, 1999; Kono et al, 2002c). Furthermore,
we have recently shown that Herceptin enhances MHC class I-
restricted antigen presentation in HER-2-overexpressing tumours,
resulting in a higher susceptibility of HER-2-overexpressing
tumours to lysis by HER-2-specific CTL (Kono et al, 2004). These
results suggested that the combination of Herceptin and anti-HER-
2-specific CTLs may result in a synergic antitumour effect in
oesophageal SCC. Anti-HER-2 immune targeting such as Herceptin
or cancer vaccination with HER-2 peptides is novel and attractive
approach for oesophageal SCC and the candidates for HER-2-
based immunotherapy were limited, but significant populations of
oesophageal SCC.
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